Skip to main content

Non-Coding Variants Program (NoVa)

Non-coding Variants Program: Finding potential causal variants

RFA HG13-013:  Interpreting Variation in Human Non-Coding Genomic Regions Using Computational Approaches and Experimental Assessment 



When the genomes of many people are sequenced, millions of sites in the genome differ among those people. Some of these genetic variants are common, such as the variants for blood types (A, B, AB, or O), while many of the variants are rare, seen in only a few people. Most of these variants do not affect disease risk, response to drugs or other traits such as height. 

How can we figure out which variants affect the function and regulation of genes?  A start to interpreting variation is a genome-wide association study (GWAS), in which the genomes of thousands of people with and without a disease or trait are compared to find the chromosomal regions that affect the disease risk or trait. In these regions, usually many variants are statistically associated with the disease or trait, but we do not know which one or few of the variants functionally affect the risk of disease or other traits.

Some variants are in the parts of the genome that code for proteins; the effects of these variants are not necessarily known, but the genetic code provides a good starting point to predict how the variants might affect protein function and thus underlie the disease or trait. However, most variants, including most of the functional ones that contribute to disease risk, are not in protein-coding regions.  These functional variants generally affect the regulation of genes or chromosome structure; they occur in "switches" in the genome that determine when and where proteins are made.

The Non-Coding Variants Program (NoVa) supports the development of approaches to figure out which of the many variants in a region associated with a disease or trait (especially the variants not coding for proteins) functionally cause the higher risk for the disease or trait. This program supports computational methods to integrate many data sets related to gene and variant function, to predict which variants (or narrow the set of potential variants) cause differences in disease risk or other traits, and to assess experimentally the accuracy of these predictions.

Determining which variants cause the disease risk or trait will allow researchers to discover the mechanisms by which these variants lead to the increased disease risk or trait.  Eventually, this understanding should allow researchers to develop approaches for prevention and therapies, as well as to make predictions about a person's risk of disease.

The six awards funded in the first round of this RFA use a range of approaches to study a variety of diseases as test cases.  All the data used and produced will be released, to allow other researchers to compare methods. 

Top of page

Grantees of the Program

Grantees Institution Title Grant Number
Phase I Grantees
Nir Hacohen Broad Institute of MIT and Harvard Non-coding genetic variants that impact immune phenotypes and diseases R01 HG008131
Manolis Kellis Broad Institute of
MIT and Harvard
Interpreting non-coding variants using epigenomics, regulatory models, and validation R01 HG008155
Alain Laederach,
Kevin Weeks
University of North Carolina at Chapel Hill Predicting the causative SNPs in LD blocks by allele-specific structural analysis R01 HG008133
Stephen Montgomery Stanford University Predicting causal non-coding variants in a founder population R01 HG008150
Bing Ren Ludwig Institute for Cancer Research, University of California, San Diego Non-coding variants predisposing to age-related macular degeneration R01 HG008135
Jay Shendure,
Gregory Cooper
University of Washington Integrative interpretation of the organismal consequences of non-coding variation R01 CA197139
Phase II Grantees
Mark Gerstein Yale University Prioritizing rare variants associated with cancer using non-coding annotation R01 HG008126
Gregory Gibson Georgia Institute of Technology eQTL mega-analysis for functional assessment of multi-enhancer gene regulation R01 HG008146
Yunlong Liu,
Todd Skaar
Indiana University-Purdue University at Indianapolis Regulation of mRNA splicing by intronic genetic variants R01 CA213466
Jonathan Pritchard Stanford University Integration of functional data and GWAS to elucidate genetic basis of disease R01 HG008140
Zhengdong Zhang Albert Einstein College of Medicine Interpreting human enhance variants with a network-regularized composite model R01 HG008153

Top of page

NoVa Awards News Releases

NIH supports new approaches to discovering DNA differences in the genome's regulatory regions that affect disease
September 14, 2016

Grants to help identify variants in the genome's regulatory regions that affect disease risk
September 21, 2015

Top of page

NoVa Funding Opportunities

Past RFA

RFA-HG-13-013: Interpreting Variation in Human Non-Coding Genomic Regions Using Computational Approaches and Experimental Assessment (R01)  [Expired]

Related Funding Opportunity

These research questions are still important, so related work may come in under the regular NIH program announcement for unsolicited research projects

Top of page

Program Contacts

Lisa Brooks, Ph.D.
Program Director, Genomic Variation Program, NHGRI

Mike Pazin, Ph.D.
Program Director, Functional Genomics Program, NHGRI

Stefanie Nelson, Ph.D.

Program Director, Genomic Epidemiology Branch, National Cancer Institute

Julia Baker
Program Analyst, NHGRI

Top of page

Last Updated: December 19, 2017